Get 20% Free Customization In This Report

Buy this report from - $4176

Nanomedicine Market by Modality (Treatments and Diagnostics), Application (Drug Delivery, Diagnostic Imaging, Vaccines, Regenerative Medicine, Implants, and Others), and Indication (Oncological Diseases, Infectious Diseases, Cardiovascular Diseases, Orthopedic Disorders, Neurological Diseases, Urological Diseases, Ophthalmological Diseases, Immunological Diseases, and Others) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Pharmaceuticals	LI_172021	Pages: 190	Aug 2017 \| 2761 Views
Author's : Garima Chandra & Divya Srivastava	Tables: 92	Charts: 36	Formats*:

Nanomedicine Market Overview:

Global Nanomedicine Market accounted for $111,912 million in 2016, and is anticipated to reach $261,063 million by 2023, registering a CAGR of 12.6% from 2017 to 2023. Nanomedicine is one of the applications of nanotechnology used in diagnosis, treatment, monitoring, and control of biological systems. Nanomedicine uses nanoscale manipulation of materials to improve medicine delivery. Thus, nanomedicine has facilitated the treatment against various diseases. Nanomedicine is in nascent stage, as several products are in the development phase. According to Nanobiotix (a nanomedicine company), in 2015, around 230 nanomedicine products were identified, which are either marked or are in the trial phase. Moreover, as per the company, there are 49 nanomedicine products in the market, whereas 122 products are in the clinical pipeline either in Phase II or Phase III trials.

The global nanomedicine market is segmented based on modality, application, indication, and region. Based on application, it is classified into drug delivery, diagnostic imaging, vaccines, regenerative medicine, implants, and others. On the basis of indication, it is categorized into oncological diseases, neurological diseases, urological diseases, infectious diseases, ophthalmological diseases, orthopedic disorders, immunological diseases, cardiovascular diseases, and others. Based on modality, it is bifurcated into treatments and diagnostics. Regionally, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Drivers, Restraints, and Opportunities

The global nanomedicine market is driven by emerging technologies for drug delivery, increase in adoption of nanomedicine across varied applications, rise in government support & funding, growth in need for therapies with fewer side effects, and cost-effectiveness of therapies. However, long approval process and risks associated with nanomedicine (environmental impacts) restrain the market growth. In addition, increase in out-licensing of nanodrugs and growth of healthcare facilities in emerging economies are anticipated to provide numerous opportunities for the growth of nanomedicine market.

India Nanomedicine Market

Increase in adoption of novel nanomedicines products drives the market growth in India. Moreover, increase in the number of players and high adoption of innovative technologies further fuel the market growth. In addition, robust government initiative toward improvement of healthcare facilities through insurance schemes is anticipated to provide lucrative growth opportunities in the country. The nanomedicines market in India is expected to grow at the highest CAGR of 13.4% from 2016 to 2023.

The key players operating in the global nanomedicine market are Abbott Laboratories, CombiMatrix Corporation, General Electric Company, Sigma-Tau Pharmaceuticals, Inc., Johnson & Johnson, Mallinckrodt plc., Merck & Company, Inc., Nanosphere, Inc., Pfizer, Inc., and Teva Pharmaceutical Industries Ltd.

The other prominent players in the value chain include Celgene Corporation, UCB (Union Chimique Belge) S.A., AMAG Pharmaceuticals, Nanospectra Biosciences, Inc., Arrowhead Pharmaceuticals, Inc., Leadiant Biosciences, Inc., Epeius Biotechnologies Corporation
Gilead, and Cytimmune Sciences, Inc.

Key Benefits

The study provides an in-depth analysis of the global nanomedicine market and the current trends and future estimations to elucidate the imminent investment pockets.
The report presents quantitative analysis of the market from 2016 to 2023 to enable stakeholders to capitalize on the prevailing market opportunities.
Extensive analysis of the market based on product assists in understanding the trends in the industry.
Key market players and their strategies are thoroughly analyzed to understand the competitive outlook of the industry.

Nanomedicine Market Key Segments:

By Application

Drug Delivery
Vaccines
Diagnostic Imaging
Regenerative Medicine
Implants
Others

By Modality

Diagnostics
Treatments

By Indication

Oncological Diseases
Infectious Diseases
Cardiovascular Diseases
Orthopedic Disorders
Neurological Diseases
Urological Diseases
Ophthalmological Diseases
Immunological Diseases
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- Rest of Asia-Pacific
LAMEA
- Brazil
- Argentina
- Saudi Arabia
- South Africa
- Rest of LAMEA

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE
2.3. MARKET DEFINITION AND SCOPE
2.4. KEY FINDINGS

2.4.1. Top investment pockets
2.4.2. Top winning strategies

2.5. PORTER’S FIVE FORCES ANALYSIS
2.6. REGULATION AND REIMBURSEMENT SCENARIO

2.6.1. Fda
2.6.2. Health canada
2.6.3. Ce mark
2.6.4. Ministry of health, labor, and welfare (mhlw)

2.7. MARKET SHARE ANALYSIS, 2016
2.8. MARKET DYNAMICS

2.8.1. Drivers

2.8.1.1. Emerging innovative technologies for drug delivery
2.8.1.2. Increase adoption of nanomedicine across varied applications
2.8.1.3. Rise in government support and funding
2.8.1.4. Growth in need of therapies that have fewer side effects and are cost effective

2.8.2. Restraints

2.8.2.1. Long approval process
2.8.2.2. Risks associated with nanomedicine (environmental impacts)

2.8.3. Opportunities

2.8.3.1. Growth of healthcare facilities in emerging economies

Chapter: 3 NANOMEDICINE MARKET, BY APPLICATION

3.1. OVERVIEW

3.1.1. Market size and forecast

3.2. VACCINES

3.2.1. Key market trends
3.2.2. Growth factors and opportunities
3.2.3. Market size and forecast

3.3. REGENERATIVE MEDICINE

3.3.1. Key market trends
3.3.2. Growth factors and opportunities
3.3.3. Market size and forecast

3.4. DIAGNOSTIC IMAGING

3.4.1. Key market trends
3.4.2. Growth factors and opportunities
3.4.3. Market size and forecast

3.5. DRUG DELIVERY

3.5.1. Key market trends
3.5.2. Growth factors and opportunities
3.5.3. Market size and forecast

3.6. IMPLANTS

3.6.1. Key market trends
3.6.2. Growth factors and opportunities
3.6.3. Market size and forecast

3.7. OTHERS

3.7.1. Key market trends
3.7.2. Growth factors and opportunities
3.7.3. Market size and forecast

Chapter: 4 NANOMEDICINE MARKET, BY INDICATION

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. ONCOLOGICAL DISEASES

4.2.1. Market size and forecast

4.3. INFECTIOUS DISEASES

4.3.1. Market size and forecast

4.4. CARDIOVASCULAR DISEASES

4.4.1. Market size and forecast

4.5. ORTHOPEDIC DISORDERS

4.5.1. Market size and forecast

4.6. NEUROLOGICAL DISORDERS

4.6.1. Market size and forecast

4.7. UROLOGICAL DISEASES

4.7.1. Market size and forecast

4.8. OPHTHALMOLOGICAL DISEASES

4.8.1. Market size and forecast

4.9. IMMUNOLOGICAL DISEASES

4.9.1. Market size and forecast

4.10. OTHERS

4.10.1. Market size and forecast

Chapter: 5 NANOMEDICINE MARKET, BY MODALITY

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. TREATMENTS

5.2.1. Market size and forecast

5.3. DIAGNOSTICS

5.3.1. Market size and forecast

Chapter: 6 NANOMEDICINE MARKET, BY REGION

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. North America market size and forecast for nanomedicine market by country
6.2.4. North America market size and forecast for nanomedicine market by application
6.2.5. North America market size and forecast for nanomedicine market by indication
6.2.6. North America market size and forecast for nanomedicine market by modality

6.2.6.1. U.S. Market size and forecast for nanomedicine market by application
6.2.6.2. U.S. Market size and forecast for nanomedicine market by indication
6.2.6.3. U.S. Market size and forecast for nanomedicine market by modality
6.2.6.4. Canada market size and forecast for nanomedicine market by application
6.2.6.5. Canada market size and forecast for nanomedicine market by indication
6.2.6.6. Canada market size and forecast for nanomedicine market by modality
6.2.6.7. Mexico market size and forecast for nanomedicine market by application
6.2.6.8. Mexico market size and forecast for nanomedicine market by indication
6.2.6.9. Mexico market size and forecast for nanomedicine market by modality

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Europe market size and forecast for nanomedicine market by country
6.3.4. Europe market size and forecast for nanomedicine market by application
6.3.5. Europe market size and forecast for nanomedicine market by indication
6.3.6. Europe market size and forecast for nanomedicine market by modality

6.3.6.1. Germany market size and forecast for nanomedicine market by application
6.3.6.2. Germany market size and forecast for nanomedicine market by indication
6.3.6.3. Germany market size and forecast for nanomedicine market by modality
6.3.6.4. UK market size and forecast for nanomedicine market by application
6.3.6.5. UK market size and forecast for nanomedicine market by indication
6.3.6.6. UK market size and forecast for nanomedicine market by modality
6.3.6.7. France market size and forecast for nanomedicine market by application
6.3.6.8. France market size and forecast for nanomedicine market by indication
6.3.6.9. France market size and forecast for nanomedicine market by modality
6.3.6.10. Italy market size and forecast for nanomedicine market by application
6.3.6.11. Italy market size and forecast for nanomedicine market by indication
6.3.6.12. Italy market size and forecast for nanomedicine market by modality
6.3.6.13. Spain market size and forecast for nanomedicine market by application
6.3.6.14. Spain market size and forecast for nanomedicine market by indication
6.3.6.15. Spain market size and forecast for nanomedicine market by modality
6.3.6.16. Rest of Europe market size and forecast for nanomedicine market by application
6.3.6.17. Rest of Europe market size and forecast for nanomedicine market by indication
6.3.6.18. Rest of Europe market size and forecast for nanomedicine market by modality

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Asia-Pacific market size and forecast for nanomedicine market by country
6.4.4. Asia-Pacific market size and forecast for nanomedicine market by application
6.4.5. Asia-Pacific market size and forecast for nanomedicine market by indication
6.4.6. Asia-Pacific market size and forecast for nanomedicine market by modality

6.4.6.1. China market size and forecast for nanomedicine market by application
6.4.6.2. China market size and forecast for nanomedicine market by indication
6.4.6.3. China market size and forecast for nanomedicine market by modality
6.4.6.4. Japan market size and forecast for nanomedicine market by application
6.4.6.5. Japan market size and forecast for nanomedicine market by indication
6.4.6.6. Japan market size and forecast for nanomedicine market by modality
6.4.6.7. India market size and forecast for nanomedicine market by application
6.4.6.8. India market size and forecast for nanomedicine market by indication
6.4.6.9. India market size and forecast for nanomedicine market by modality
6.4.6.10. Australia market size and forecast for nanomedicine market by application
6.4.6.11. Australia market size and forecast for nanomedicine market by indication
6.4.6.12. Australia market size and forecast for nanomedicine market by modality
6.4.6.13. Rest of Asia-Pacific market size and forecast for nanomedicine market by application
6.4.6.14. Rest of Asia-Pacific market size and forecast for nanomedicine market by indication
6.4.6.15. Rest of Asia-Pacific market size and forecast for nanomedicine market by modality

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. LAMEA market size and forecast for nanomedicine market by country
6.5.4. LAMEA market size and forecast for nanomedicine market by application
6.5.5. LAMEA market size and forecast for nanomedicine market by indication
6.5.6. LAMEA market size and forecast for nanomedicine market by modality

6.5.6.1. Brazil market size and forecast for nanomedicine market by application
6.5.6.2. Brazil market size and forecast for nanomedicine market by indication
6.5.6.3. Brazil market size and forecast for nanomedicine market by modality
6.5.6.4. South Africa market size and forecast for nanomedicine market by application
6.5.6.5. South Africa market size and forecast for nanomedicine market by indication
6.5.6.6. South Africa market size and forecast for nanomedicine market by modality
6.5.6.7. Saudi Arabia market size and forecast for nanomedicine market by application
6.5.6.8. Saudi Arabia market size and forecast for nanomedicine market by indication
6.5.6.9. Saudi Arabia market size and forecast for nanomedicine market by modality
6.5.6.10. Argentina market size and forecast for nanomedicine market by application
6.5.6.11. Argentina market size and forecast for nanomedicine market by indication
6.5.6.12. Argentina market size and forecast for nanomedicine market by modality
6.5.6.13. Rest of LAMEA market size and forecast for nanomedicine market by application
6.5.6.14. Rest of LAMEA market size and forecast for nanomedicine market by indication
6.5.6.15. Rest of LAMEA market size and forecast for nanomedicine market by modality

Chapter: 7 COMPANY PROFILES

7.1. ABBOTT LABORATORIES

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance

7.2. COMBIMATRIX CORPORATION

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Business performance

7.3. GENERAL ELECTRIC COMPANY

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance

7.4. JOHNSON & JOHNSON

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance

7.5. MALLINCKRODT PLC.

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Business performance

7.6. MERCK & CO., INC.

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Business performance

7.7. LUMINEX CORPORATION

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.7.6. Key strategic moves and developments

7.8. PFIZER INC.

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance

7.9. LEADIANT BIOSCIENCES, INC. (SIGMA-TAU PHARMACEUTICALS)

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Product portfolio
7.9.4. Business performance

7.10. TEVA PHARMACEUTICAL INDUSTRIES LTD.

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance

LIST OF TABLES

TABLE 1. DIFFERENT APPROVED PRODUCT OF GLOBAL NANOMEDICINE MARKET
TABLE 2. GLOBAL NANOMEDICINE MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 3. GLOBAL NANOMEDICINE MARKET FOR VACCINES APPLICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 4. GLOBAL NANOMEDICINE MARKET FOR REGENERATIVE MEDICINE APPLICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 5. GLOBAL NANOMEDICINE MARKET FOR DIAGNOSTIC IMAGING APPLICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 6. GLOBAL NANOMEDICINE MARKET FOR DRUG DELIVERY APPLICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 7. GLOBAL NANOMEDICINE MARKET FOR IMPLANTS APPLICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 8. GLOBAL NANOMEDICINE MARKET FOR OTHERS APPLICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 9. GLOBAL NANOMEDICINE MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 10. GLOBAL NANOMEDICINE MARKET FOR ONCOLOGICAL DISEASES INDICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 11. GLOBAL NANOMEDICINE MARKET FOR INFECTIOUS DISEASES INDICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 12. GLOBAL NANOMEDICINE MARKET FOR CARDIOVASCULAR DISEASES INDICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 13. GLOBAL NANOMEDICINE MARKET FOR ORTHOPEDIC DIORDERS INDICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 14. GLOBAL NANOMEDICINE MARKET FOR NEUROLOGICAL DISORDERS INDICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 15. GLOBAL NANOMEDICINE MARKET FOR UROLOGICAL DISEASES INDICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 16. GLOBAL NANOMEDICINE MARKET FOR OPHTHALMOLOGICAL DISEASES INDICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 17. GLOBAL NANOMEDICINE MARKET FOR IMMUNOLOGICAL DISEASES INDICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 18. GLOBAL NANOMEDICINE MARKET FOR OTHERS INDICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 19. GLOBAL NANOMEDICINE MARKET, BY MODALITY, 2016-2023 ($MILLION)
TABLE 20. GLOBAL NANOMEDICINE MARKET FOR TREATMENT MODALITY, BY REGION, 2016-2023 ($MILLION)
TABLE 21. GLOBAL NANOMEDICINE MARKET FOR DIAGNOSTICS MODALITY, BY REGION, 2016-2023 ($MILLION)
TABLE 22. NANOMEDICINE MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 23. NORTH AMERICA NANOMEDICINE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 24. NORTH AMERICA NANOMEDICINE MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 25. NORTH AMERICA NANOMEDICINE MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 26. NORTH AMERICA NANOMEDICINE MARKET, BY MODALITY, 2016-2023 ($MILLION)
TABLE 27. U.S. MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY APPLICATION, 2016-2023 ($MILLION)
TABLE 28. U.S. MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY INDICATION, 2016-2023 ($MILLION)
TABLE 29. U.S. MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY MODALITY, 2016-2023 ($MILLION)
TABLE 30. CANADA MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY APPLICATION, 2016-2023 ($MILLION)
TABLE 31. CANADA MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY INDICATION, 2016-2023 ($MILLION)
TABLE 32. CANADA MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY MODALITY, 2016-2023 ($MILLION)
TABLE 33. MEXICO MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY APPLICATION, 2016-2023 ($MILLION)
TABLE 34. MEXICO MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY INDICATION, 2016-2023 ($MILLION)
TABLE 35. MEXICO MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY MODALITY, 2016-2023 ($MILLION)
TABLE 36. EUROPE NANOMEDICINE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 37. EUROPE NANOMEDICINE MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 38. EUROPE NANOMEDICINE MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 39. EUROPE NANOMEDICINE MARKET, BY MODALITY, 2016-2023 ($MILLION)
TABLE 40. GERMANY MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY APPLICATION, 2016-2023 ($MILLION)
TABLE 41. GERMANY MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY INDICATION, 2016-2023 ($MILLION)
TABLE 42. GERMANY MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY MODALITY, 2016-2023 ($MILLION)
TABLE 43. UK MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY APPLICATION, 2016-2023 ($MILLION)
TABLE 44. UK MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY INDICATION, 2016-2023 ($MILLION)
TABLE 45. UK MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY MODALITY, 2016-2023 ($MILLION)
TABLE 46. FRANCE MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY APPLICATION, 2016-2023 ($MILLION)
TABLE 47. FRANCE MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY INDICATION, 2016-2023 ($MILLION)
TABLE 48. FRANCE MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY MODALITY, 2016-2023 ($MILLION)
TABLE 49. ITALY MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY APPLICATION, 2016-2023 ($MILLION)
TABLE 50. ITALY MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY INDICATION, 2016-2023 ($MILLION)
TABLE 51. ITALY MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY MODALITY, 2016-2023 ($MILLION)
TABLE 52. SPAIN MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY APPLICATION, 2016-2023 ($MILLION)
TABLE 53. SPAIN MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY INDICATION, 2016-2023 ($MILLION)
TABLE 54. SPAIN MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY MODALITY, 2016-2023 ($MILLION)
TABLE 55. REST OF EUROPE MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY APPLICATION, 2016-2023 ($MILLION)
TABLE 56. REST OF EUROPE MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY INDICATION, 2016-2023 ($MILLION)
TABLE 57. REST OF EUROPE MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY MODALITY, 2016-2023 ($MILLION)
TABLE 58. ASIA-PACIFIC NANOMEDICINE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 59. ASIA-PACIFIC NANOMEDICINE MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 60. ASIA-PACIFIC NANOMEDICINE MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 61. ASIA-PACIFIC NANOMEDICINE MARKET, BY MODALITY, 2016-2023 ($MILLION)
TABLE 62. CHINA MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY APPLICATION, 2016-2023 ($MILLION)
TABLE 63. CHINA MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY INDICATION, 2016-2023 ($MILLION)
TABLE 64. CHINA MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY MODALITY, 2016-2023 ($MILLION)
TABLE 65. JAPAN MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY APPLICATION, 2016-2023 ($MILLION)
TABLE 66. JAPAN MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY INDICATION, 2016-2023 ($MILLION)
TABLE 67. JAPAN MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY MODALITY, 2016-2023 ($MILLION)
TABLE 68. INDIA MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY APPLICATION, 2016-2023 ($MILLION)
TABLE 69. INDIA MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY INDICATION, 2016-2023 ($MILLION)
TABLE 70. INDIA MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY MODALITY, 2016-2023 ($MILLION)
TABLE 71. AUSTRALIA MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY APPLICATION, 2016-2023 ($MILLION)
TABLE 72. AUSTRALIA MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY INDICATION, 2016-2023 ($MILLION)
TABLE 73. AUSTRALIA MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY MODALITY, 2016-2023 ($MILLION)
TABLE 74. REST OF ASIA-PACIFIC MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY APPLICATION, 2016-2023 ($MILLION)
TABLE 75. REST OF ASIA-PACIFIC MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY INDICATION, 2016-2023 ($MILLION)
TABLE 76. REST OF ASIA-PACIFIC MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY MODALITY, 2016-2023 ($MILLION)
TABLE 77. LAMEA NANOMEDICINE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 78. LAMEA NANOMEDICINE MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 79. LAMEA NANOMEDICINE MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 80. LAMEA NANOMEDICINE MARKET, BY MODALITY, 2016-2023 ($MILLION)
TABLE 81. BRAZIL MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY APPLICATION, 2016-2023 ($MILLION)
TABLE 82. BRAZIL MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY INDICATION, 2016-2023 ($MILLION)
TABLE 83. BRAZIL MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY MODALITY, 2016-2023 ($MILLION)
TABLE 84. SOUTH AFRICA MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY APPLICATION, 2016-2023 ($MILLION)
TABLE 85. SOUTH AFRICA MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY INDICATION, 2016-2023 ($MILLION)
TABLE 86. SOUTH AFRICA MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY MODALITY, 2016-2023 ($MILLION)
TABLE 87. SAUDI ARABIA MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY APPLICATION, 2016-2023 ($MILLION)
TABLE 88. SAUDI ARABIA MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY INDICATION, 2016-2023 ($MILLION)
TABLE 89. SAUDI ARABIA MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY MODALITY, 2016-2023 ($MILLION)
TABLE 90. ARGENTINA MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY APPLICATION, 2016-2023 ($MILLION)
TABLE 91. ARGENTINA MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY INDICATION, 2016-2023 ($MILLION)
TABLE 92. ARGENTINA MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY MODALITY, 2016-2023 ($MILLION)
TABLE 93. REST OF LAMEA MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY APPLICATION, 2016-2023 ($MILLION)
TABLE 94. REST OF LAMEA MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY INDICATION, 2016-2023 ($MILLION)
TABLE 95. REST OF LAMEA MARKET SIZE AND FORECAST FOR NANOMEDICINE MARKET BY MODALITY, 2016-2023 ($MILLION)
TABLE 96. ABBOTT: COMPANY SNAPSHOT
TABLE 97. ABBOTT: OPERATING SEGMENTS
TABLE 98. ABBOTT: PRODUCT PORTFOLIO
TABLE 99. COMBIMATRIX CORPORATION: COMPANY SNAPSHOT
TABLE 100. COMBIMATRIX CORPORATION: OPERATING SEGMENTS
TABLE 101. GE HEALTHCARE: COMPANY SNAPSHOT
TABLE 102. GE HEALTHCARE: OPERATING SEGMENTS
TABLE 103. GE HEALTHCARE: PRODUCT PORTFOLIO
TABLE 104. J&J: COMPANY SNAPSHOT
TABLE 105. J&J: OPERATING SEGMENTS
TABLE 106. J&J: PRODUCT PORTFOLIO
TABLE 107. MALLINCKRODT: COMPANY SNAPSHOT
TABLE 108. MALLINCKRODT: OPERATING SEGMENTS
TABLE 109. MERCK: COMPANY SNAPSHOT
TABLE 110. MERCK: OPERATING SEGMENTS
TABLE 111. LUMINEX: COMPANY SNAPSHOT
TABLE 112. LUMINEX: OPERATING SEGMENTS
TABLE 113. LUMINEX: PRODUCT PORTFOLIO
TABLE 114. PFIZER: COMPANY SNAPSHOT
TABLE 115. PFIZER: OPERATING SEGMENTS
TABLE 116. LEADIANT BIOSCIENCES: COMPANY SNAPSHOT
TABLE 117. LEADIANT BIOSCIENCES: PRODUCT PORTFOLIO
TABLE 118. TEVA: COMPANY SNAPSHOT
TABLE 119. TEVA: OPERATING SEGMENTS
TABLE 120. TEVA: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 1. SNAPSHOT GLOBAL NANOMEDICINE MARKET, 2016-2023
FIGURE 2. TOP INVESTMENT POCKETS IN GLOBAL NANOMEDICINE MARKET
FIGURE 3. TOTAL NUMBER OF STRATEGIES: GLOBAL NANOMEDICINE MARKET
FIGURE 4. BARGAINING POWER OF BUYERS
FIGURE 5. BARGAINING POWER OF SUPPLIERS
FIGURE 6. THREAT OF NEW ENTRANTS
FIGURE 7. THREAT OF SUBSTITUTION
FIGURE 8. COMPETITIVE RIVALRY
FIGURE 9. MARKET SHARE ANALYSIS: NANOMEDICINE MARKET, 2016
FIGURE 10. RESTRAINTS AND DRIVERS: GLOBAL NANOMEDICINE MARKET
FIGURE 11. GLOBAL NANOMEDICINE MARKET, BY APPLICATION
FIGURE 12. NANOMEDICINE MARKET, BY INDICATION
FIGURE 13. NANOMEDICINE MARKET, BY REGION
FIGURE 14. ABBOTT: NET SALES, 2014-2016 ($MILLION)
FIGURE 15. ABBOTT: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 16. ABBOTT: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 17. COMBIMATRIX CORPORATION: NET SALES, 2014-2016 ($MILLION)
FIGURE 18. GE HEALTHCARE: REVENUE, 2014-2016 ($MILLION)
FIGURE 19. GE HEALTHCARE: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 20. GE HEALTHCARE: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 21. J&J: REVENUE, 2014-2016 ($MILLION)
FIGURE 22. J&J: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 23. J&J: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 24. MALLINCKRODT: NET SALES, 2014-2016 ($MILLION)
FIGURE 25. MALLINCKRODT: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 26. MALLINCKRODT: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 27. MERCK: REVENUE, 2014-2016 ($MILLION)
FIGURE 28. MERCK: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 29. MERCK: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 30. LUMINEX: NET SALES, 2014-2016 ($MILLION)
FIGURE 31. LUMINEX: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 32. PFIZER: REVENUE, 2014-2016 ($MILLION)
FIGURE 33. PFIZER: REVENUE SHARE BY SEGMENT, 2016 ($MILLION)
FIGURE 34. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2016 ($MILLION)
FIGURE 35. TEVA: NET SALES, 2014-2016 ($MILLION)
FIGURE 36. TEVA: REVENUE SHARE BY SEGMENT, 2016 (%)

Nanomedicines is an emerging and most promising technology in the 21st century. This is due to the fact that it involves the drug development at molecular scale which helps in easy prevention, diagnosis, treatment, and regeneration of tissues and organs. Thus, these help to preserve and improve human health by offering impressive solutions for several life-threatening diseases such as cancer, Alzheimer’s disease, Parkinson’s disease, diabetes, orthopedic problems, diseases related to blood, neurological, lungs, and cardiovascular system.

The healthcare market has witnessed rapid development in the recent years, thus emerging players have focused on expanding their presence in the nanomedicine sector. Moreover, key players have contributed significantly to the market growth by leveraging product diversification, product commercialization, and product approvals.

In the diagnosis field, nanomedicine is a cost-effective technique as it requires minimum amount of biological sample, which reduces consumption of disposables and reagents. Moreover, apart from diagnostics, nanomedicine assists in drug delivery by utilizing nanoscale particles with larger surface-to-volume ratio. These particles are allowed to enter into body cavities for the diagnosis or treatment of diseases; thereby, improving the efficacy of treatment and diagnosis and preventing side effects of drugs in case of targeted therapy.

Shopping Cart is Empty..

Your Shopping Cart Is Empty

Nanomedicine Market Overview: